You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
励晶太平洋(00575.HK):合作夥伴万邦医药临床试验申请获准提交
阿思达克 12-02 12:22
励晶太平洋(00575.HK)就有关Senstend╱Fortacin之营运最新情况作出公布,商业战略夥伴江苏万邦医药已获得国家药监局批准提交试验性新药申请以就一款许可产品开展人类临床试验,作为达成批准在中国市场推广Senstend之重要里程碑。

因此,公司附属Plethora已向江苏万邦医药出具80万美元的发票,须於30个营业日内支付。

国家药监局将正式审阅临床试验审批,而公司接获江苏万邦医药通知,将会於提交日期起计60个工作天内(即明年第一季度完结之前)取得药品审评中心的临床试验审批。成功获得药监局批准开始临床试验後,320万美元将会到期并需支付。

根据早前许可协议,Plethora将治疗早泄药品Fortacin於内地商业化权利授予万邦医药。在达到与中国销售有关之若干里程碑後,集团将有权收取最多为3,800万美元之付款,不包括特许权使用费。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account